Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > The week ahead

<< Previous

Bullboard Posts

Next >>

Comment by Normandton Oct 31, 2023 10:09am

178 Views

Post# 35709067

RE:RE:RE:RE:RE:RE:The week ahead

 hello Azzak, I don't like confrontation, but you read it wrong. It doesn't say blah, but blah blah- blah, I reread the press releases twice. I'm right, because I fought in the first war and I won it, that's why I have a blog where you can follow me: DeMan/ultraman/spiderman/differentusernames_Ilovetotalkwithmyself. Above all, don't listen to analysts, listen to those who have been here for more than 25 years, they are the best. By the way, do you have the link, so I can see the "blah" curve you're talking about, even if you're wrong

<< Previous

Bullboard Posts

Next >>

Dollar Tree CEO Rick Dreiling steps down as discount retailer struggles